US FDA accepts MS drug Lemtrada resubmission for review
US FDA accepts MS drug Lemtrada resubmission for review
The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1826 Views
-
Last post by frodo
-
- 0 Replies
- 1172 Views
-
Last post by NHE
-
- 0 Replies
- 1647 Views
-
Last post by frodo
-
- 0 Replies
- 1175 Views
-
Last post by frodo
-
- 1 Replies
- 1609 Views
-
Last post by frodo
-
- 0 Replies
- 1966 Views
-
Last post by NHE
-
- 0 Replies
- 2220 Views
-
Last post by NHE
-
- 0 Replies
- 1022 Views
-
Last post by frodo
-
- 1 Replies
- 1344 Views
-
Last post by NHE